Medications for Heart Failure Market Report 2026

The medications for heart failure market size has grown strongly in recent years. It will grow from $10.79 billion in 2025 to $11.53 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, aging global population, rising incidence of hypertension and diabetes, improved access to essential cardiac medications, expansion of hospital-based cardiac care.

The medications for heart failure market size is expected to see strong growth in the next few years. It will grow to $15.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growth in heart failure patient population, increasing adoption of novel drug classes, rising focus on personalized cardiovascular therapy, expansion of outpatient and home-based care models, stronger emphasis on preventive cardiology. Major trends in the forecast period include rising adoption of combination drug therapies, growing use of SGLT2 inhibitors in heart failure treatment, increasing focus on early diagnosis and long-term disease management, expansion of evidence-based treatment guidelines, higher emphasis on reducing heart failure hospitalizations.

The rising prevalence of cardiovascular diseases is expected to drive growth in the heart failure medications market in the coming years. Cardiovascular diseases are disorders that impact the heart and blood vessels, often resulting in severe complications such as heart attacks and strokes. This rise in cardiovascular diseases is largely attributed to sedentary lifestyles, which gradually impair heart and vessel health. As the occurrence of cardiovascular diseases increases, the demand for effective treatments also grows, promoting greater investment in heart failure medications. With the condition becoming more widespread, pharmaceutical companies are concentrating on developing and enhancing therapies to better manage symptoms and improve patient outcomes. For instance, in September 2024, the Heart Failure Society of America (HFSA), a U.S.-based organization of heart failure specialists, reported that around 6.7 million Americans aged 20 and older are currently living with heart failure (HF), with projections reaching 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. As a result, the increasing prevalence of cardiovascular diseases is driving growth in the heart failure medications market.

Major companies operating in the medication for heart failure market are concentrating on developing advanced therapies, such as sodium-glucose cotransporter (SGLT) inhibitors, to enable more effective long-term management of heart failure symptoms and related complications. An SGLT inhibitor is a sophisticated medication that targets glucose reabsorption pathways to support heart failure management, improve efficiency, and optimize cardiovascular health. For example, in May 2023, Lexicon Pharmaceuticals, a U.S.-based biopharmaceutical company, launched Inpefa (sotagliflozin), which received approval from the Food and Drug Administration (FDA). It is a once-daily oral tablet intended to lower the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval represents a key milestone for Lexicon, as Inpefa is the first dual SGLT1/SGLT2 inhibitor to enter the market, providing a new therapeutic option for heart failure patients across a wide range of conditions.

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired Cardior Pharmaceuticals for $1.112 billion. The acquisition is aimed at enhancing Novo Nordisk's cardiovascular disease pipeline, particularly with Cardior's lead compound CDR132L, which is in phase 2 clinical development for the treatment of heart failure. Cardior Pharmaceuticals, based in Germany, focuses on the research of oligonucleotide-based inhibitors for managing heart failure.

Major companies operating in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol‑Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Hainan Poly Pharm Co Ltd, Lunan Pharmaceutical Group, Mylan Laboratories Inc., JM Laboratories, Lexicon Pharmaceuticals, Pfizer Inc, Johnson & Johnson, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Amgen Inc, Otsuka Pharmaceutical Co Ltd.

North America was the largest region in the medications for the heart failure market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medications for heart failure market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medications for heart failure market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the medications for heart failure market by increasing costs related to imported active pharmaceutical ingredients, excipients, and finished drug formulations. The impact is most evident in branded and advanced therapies, particularly in regions dependent on imported pharmaceuticals such as Asia-Pacific and Latin America. Higher input costs have influenced pricing and reimbursement dynamics across hospital and retail pharmacy channels. However, tariffs have also encouraged domestic drug manufacturing, local API production, and supply chain diversification, supporting long-term market resilience.

The medications for heart failure market research report is one of a series of new reports that provides medications for heart failure market statistics, including medications for heart failure industry global market size, regional shares, competitors with a medications for heart failure market share, detailed medications for heart failure market segments, market trends and opportunities, and any further data you may need to thrive in the medications for heart failure industry. This medications for heart failure market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medications for heart failure are drugs used to treat and manage heart failure, a condition in which the heart is unable to pump blood efficiently to meet the body's needs. These medications help enhance heart function, alleviate symptoms, prevent hospital admissions, and improve survival.

The main drug classes used for heart failure include angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, aldosterone antagonists, angiotensin II receptor blockers (ARBs), and others. ACE inhibitors work by relaxing blood vessels through the inhibition of angiotensin II formation, lowering blood pressure, and reducing the heart's workload. They are commonly prescribed for heart failure and high blood pressure. These medications are administered via different routes, such as oral and intravenous, and are made available through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, for use in settings like hospitals, clinics, and others.

The medications for the heart failure market consist of sales of angiotensin receptor-neprilysin inhibitors, hydralazine and nitrates, ivabradine, and digoxin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.